NCT04733092View on ClinicalTrials.gov

Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

June 20, 2022

Study Completion Date

September 20, 2022

Conditions
Knee Osteoarthritis
Interventions
DRUG

Lipiodol

Lipiodol in emulsion with contrast agent

Trial Locations (1)

75015

Hôpital européen Georges Pompidou, Paris

Sponsors

Collaborators (1)

Guerbet
All Listed Sponsors
collaborator

Guerbet

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04733092 - Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1) | Biotech Hunter | Biotech Hunter